SAB Biotherapeutics (SABS) Q4 2024 Annual Earnings
SABS·Reported March 28, 2025·Before market open
SAB Biotherapeutics reported Q4 2024 revenue of $100.0K, missed analyst consensus of $120.0K by $20.0K. Diluted EPS came in at $-1.23, missed the $-1.16 consensus by $0.07.
Revenue
$100.0Kmissed by $20.0K
Consensus: $120.0KDiluted EPS
$-1.23missed by $0.07
Consensus: $-1.16
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about SAB Biotherapeutics's Q4 2024 earnings report.
SAB Biotherapeutics (SABS) reported Q4 2024 earnings on March 28, 2025 before market open.
SAB Biotherapeutics reported revenue of $100.0K and diluted EPS of $-1.23 for Q4 2024.
Revenue missed the consensus estimate of $120.0K by $20.0K. EPS missed the consensus estimate of $-1.16 by $0.07.
You can read the 10-K periodic report (0000950170-25-046994) directly on SEC EDGAR. The filing index links above go to sec.gov.